Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
| Autor: | Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Cancer Research Neoplasm Residual Neoplasms Hormone-Dependent Receptor ErbB-2 medicine.medical_treatment Estrogen receptor Breast Neoplasms Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies Survival rate Neoadjuvant therapy Triple-negative breast cancer Aged Neoplasm Staging Aged 80 and over Gynecology business.industry Carcinoma Ductal Breast Cancer Triple Negative Breast Neoplasms Middle Aged Prognosis medicine.disease Neoadjuvant Therapy Survival Rate Receptors Estrogen Chemotherapy Adjuvant Female Breast disease Neoplasm Recurrence Local Receptors Progesterone business |
| Zdroj: | Journal of Clinical Oncology. 41:1809-1815 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC. PATIENTS AND METHODS Analysis of a prospectively collected clinical database was performed. We included 1,118 patients who received neoadjuvant chemotherapy at M.D. Anderson Cancer Center for stage I-III breast cancer from 1985 to 2004 and for whom complete receptor information were available. Clinical and pathologic parameters, pathologic complete response rates (pCR), survival measurements, and organ-specific relapse rates were compared between patients with TNBC and non-TNBC. RESULTS Two hundred fifty-five patients (23%) had TNBC. Patients with TNBC compared with non-TNBC had significantly higher pCR rates (22% v 11%; P = .034), but decreased 3-year progression-free survival rates ( P < .0001) and 3-year overall survival (OS) rates ( P < .0001). TNBC was associated with increased risk for visceral metastases ( P = .0005), lower risk for bone recurrence ( P = .027), and shorter postrecurrence survival ( P < .0001). Recurrence and death rates were higher for TNBC only in the first 3 years. If pCR was achieved, patients with TNBC and non-TNBC had similar survival ( P = .24). In contrast, patients with residual disease (RD) had worse OS if they had TNBC compared with non-TNBC ( P < .0001). CONCLUSION Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival. However, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with non-TNBC, particularly in the first 3 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|